Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oral anticholinergics in overactive bladder].

H Madersbacher1

  • 1Neuro-Urologische Ambulanz, LKH-Univ.-Klinik, Anichstrasse 35, A-6020 Innsbruck, Austria. helmut.madersbacher@tilak.at

Der Urologe. Ausg. A
|June 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?

International journal of clinical practice·2014
Same author

Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics.

Spinal cord·2013
Same author

Bladder compliance what does it represent: can we measure it, and is it clinically relevant?

Neurourology and urodynamics·2011
Same author

Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: A review from a clinical perspective.

Journal of pediatric urology·2010
Same author

Neurological patients need evidence-based urological care.

Neurourology and urodynamics·2010
Same author

Neurologic urinary incontinence.

Neurourology and urodynamics·2009
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Behavioral therapy and anticholinergics are key treatments for overactive bladder. Different drug properties affect side effect profiles, especially CNS effects in elderly patients.

Area of Science:

  • Pharmacology
  • Urology
  • Geriatrics

Context:

  • Overactive bladder (OAB) symptoms significantly impact quality of life.
  • Idiopathic and neurogenic detrusor overactivity are common causes of OAB.
  • Behavioral therapy and anticholinergics are established first-line treatments for OAB.

Purpose:

  • To provide an overview of anticholinergic medications used for OAB.
  • To analyze the influence of pharmacokinetics and pharmacodynamics on adverse event profiles.
  • To highlight potential central nervous system (CNS) side effects, particularly in geriatric populations.

Summary:

  • Several anticholinergics, including oxybutynin, solifenacin, and darifenacin, demonstrate comparable efficacy in treating OAB.
  • Differences in resorption, metabolism, and blood-brain barrier penetration lead to varied adverse event profiles.

Related Experiment Videos

  • Slow-release formulations and less lipophilic agents generally offer better tolerability.
  • Lipophilic anticholinergics may exacerbate cognitive impairment in elderly patients, especially those on cholinesterase inhibitors.

    • Impact:

    • Informing clinical decision-making for OAB treatment selection.
    • Guiding the choice of anticholinergics to minimize adverse events.
    • Improving patient outcomes and adherence through optimized drug selection.
    • Raising awareness of potential cognitive side effects in vulnerable patient groups.